Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Bimagrumab

Stage Phase 2Stale

Sponsor Eli Lilly and Company

Route injection

Class Myostatin/activin

Mechanism monoclonal antibody to the activin receptor type II

Sources

registry, as of 2026-07-08Stale

https://clinicaltrials.gov/study/NCT05616013

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 507. Conditions Obesity; Obese; Overweight or Obesity. A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 Placebo/30 mg/kg Bimagrumab 40.0 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 10/30 mg/kg Bimagrumab 58.1 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 30 mg/kg Bimagrumab 83.8 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 Placebo + 1.0 mg Semaglutide 73.3 Percentage of Participants With Redu

ClinicalTrials.gov NCT05616013 protocol and results modules

registry, as of 2026-03-27Stale

https://clinicaltrials.gov/study/NCT05933499

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Massachusetts General Hospital. Enrollment 63. Conditions Obesity. In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and

ClinicalTrials.gov NCT05933499 protocol and results modules

registry, as of 2025-09-24Stale

https://clinicaltrials.gov/study/NCT06901349

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes. Overall status WITHDRAWN. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 0. Conditions Obesity; Overweight. The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

ClinicalTrials.gov NCT06901349 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05616013

preserve/increase muscle mass in the presence of weight and/or fat mass loss. Bimagrumab Human monoclonal antibody to the activin receptor type II Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist Placebo Placebo

NCT05616013 description or intervention text

Studies

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Registry NCT05616013

Phase Phase 2

Status Completed

Enrollment 507

Start 2022-11-16

Primary completion 2024-05-16

Study completion 2025-06-14

Placebo/30 mg/kg Bimagrumab

Dose 30 mg

Regimen weekly

Weeks 4

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 40 %, week 48Stale

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 1 participantsStale

10/30 mg/kg Bimagrumab

Dose 30 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 58.1 %, week 48Stale

deaths

participants with diarrhoea, 27 participantsStale

participants with nausea, 15 participantsStale

participants with vomiting, 5 participantsStale

30 mg/kg Bimagrumab

Dose 30 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 97.7 %, week 48Stale

deaths

participants with diarrhoea, 25 participantsStale

participants with nausea, 20 participantsStale

participants with vomiting, 7 participantsStale

Placebo + 1.0 mg Semaglutide

Dose 1.0 mg

Regimen weekly

Weeks 4

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 73.3 %, week 48Stale

deaths

participants with diarrhoea, 19 participantsStale

participants with nausea, 25 participantsStale

participants with vomiting, 6 participantsStale

Placebo + 2.4 mg Semaglutide

Dose 2.4 mg

Regimen weekly

Weeks 4

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 92.2 %, week 48Stale

deaths

participants with diarrhoea, 21 participantsStale

participants with nausea, 26 participantsStale

participants with vomiting, 10 participantsStale

10 mg/kg Bimagrumab + 1.0 mg Semaglutide

Dose 1.0 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 97.6 %, week 48Stale

deaths

participants with diarrhoea, 27 participantsStale

participants with nausea, 23 participantsStale

participants with vomiting, 6 participantsStale

10 mg/kg Bimagrumab + 2.4 mg Semaglutide

Dose 2.4 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

participants with at least 5 percent body weight loss, 100 %, week 48Stale

deaths

participants with diarrhoea, 29 participantsStale

participants with nausea, 34 participantsStale

participants with vomiting, 10 participantsStale

30 mg/kg Bimagrumab + 1.0 mg Semaglutide

Dose 1.0 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

30 mg/kg Bimagrumab + 2.4 mg Semaglutide

Dose 2.4 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Obese; Overweight or Obesity

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

Registry NCT05933499

Phase Phase 2

Status Recruiting

Enrollment 63

Start 2025-11-05

Primary completion 2028-12-31

Study completion 2029-03-31

Catalyst Primary completion. 2028-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide + bimagrumab

Regimen daily

Weeks 52

Comparator placebo

Population Obesity

Tirzepatide + placebo

Regimen daily

Weeks 52

Population Obesity

Bimagrumab + placebo

Regimen daily

Weeks 52

Population Obesity

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Registry NCT06901349

Phase Phase 2

Status Withdrawn

Enrollment 0

Start 2025-05-23

Primary completion 2025-06-10

Study completion 2025-06-10

Catalyst Primary completion. 2025-06-10. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Bimagrumab Dose 1 + Tirzepatide Placebo

Population Obesity; Overweight

Bimagrumab Dose 2 + Tirzepatide Placebo

Population Obesity; Overweight

Tirzepatide Dose 1 + Bimagrumab Placebo

Population Obesity; Overweight

Tirzepatide Dose 2 + Bimagrumab Placebo

Population Obesity; Overweight

Bimagrumab Dose 2 + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Bimagrumab Dose 1 + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Bimagrumab Dose 2 + Tirzepatide Dose 2

Comparator placebo

Population Obesity; Overweight

Bimagrumab Dose 1 + Tirzepatide Dose 2

Comparator placebo

Population Obesity; Overweight

Bimagrumab Placebo + Tirzepatide Placebo

Population Obesity; Overweight